Terms: = Uterine cancer AND TSHR, hTSHR-I, 7253, ENSG00000165409, MGC75129, LGR3 AND Treatment
1 results:
1. Pembrolizumab in advanced recurrent endometrial cancer: A cost-effectiveness analysis.
Barrington DA; Dilley SE; Smith HJ; Straughn JM
Gynecol Oncol; 2019 May; 153(2):381-384. PubMed ID: 30808517
[TBL] [Abstract] [Full Text] [Related]
